MET and lung carcinoma: Consistent with the “tissue-first” and “plasma-first” approaches recommended by the International Association for the Study of Lung Cancer (4), as well as the tepotinib US Prescribing Information (38), a positive result from either biopsy type can be considered sufficient for MET inhibitor eligibility.